These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 22349515)

  • 1. Melanoma-induced immunosuppression and its neutralization.
    Umansky V; Sevko A
    Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-derived suppressor cells in malignant melanoma.
    Umansky V; Sevko A; Gebhardt C; Utikal J
    J Dtsch Dermatol Ges; 2014 Nov; 12(11):1021-7. PubMed ID: 25263083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into chronic inflammation-induced immunosuppression.
    Kanterman J; Sade-Feldman M; Baniyash M
    Semin Cancer Biol; 2012 Aug; 22(4):307-18. PubMed ID: 22387003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
    Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
    J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
    Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
    Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-derived suppressor cell role in tumor-related inflammation.
    Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
    Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
    Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V
    Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
    Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
    Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
    Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
    Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to the role of the immune system in melanoma.
    Margolin K
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):537-58. PubMed ID: 24880946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
    Sevko A; Michels T; Vrohlings M; Umansky L; Beckhove P; Kato M; Shurin GV; Shurin MR; Umansky V
    J Immunol; 2013 Mar; 190(5):2464-71. PubMed ID: 23359505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression associated with chronic inflammation in the tumor microenvironment.
    Wang D; DuBois RN
    Carcinogenesis; 2015 Oct; 36(10):1085-93. PubMed ID: 26354776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
    Parker KH; Beury DW; Ostrand-Rosenberg S
    Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
    Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
    Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?
    Auphan-Anezin N; Verdeil G; Grange M; Soudja SM; Wehbe M; Buferne M; Mas A; Schmitt-Verhulst AM
    Pigment Cell Melanoma Res; 2013 Mar; 26(2):167-75. PubMed ID: 23217139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid regulatory cells in tumor spreading and metastasis.
    Keskinov AA; Shurin MR
    Immunobiology; 2015 Feb; 220(2):236-42. PubMed ID: 25178934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
    Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
    J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.
    Umansky V; Blattner C; Gebhardt C; Utikal J
    Cancer Immunol Immunother; 2017 Aug; 66(8):1015-1023. PubMed ID: 28382399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
    Gajewski TF
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2326s-2330s. PubMed ID: 16609053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.